Published in Hepatitis Weekly, September 4th, 2006
"A prospective randomized trial was undertaken to test the efficacy of low and standard doses of pegylated interferon alpha-2b in combination with ribavirin for the initial treatment of chronic hepatitis C," wrote E.L. Krawitt and colleagues, University of Vermont.
They continued, "By nature of its design the study also provided data on response to therapy over a spectrum of doses of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.